Detalhe da pesquisa
1.
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
BMC Cancer
; 18(1): 129, 2018 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29394917
2.
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Oncologist
; 20(3): 243-4, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637380
3.
Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Clin Breast Cancer
; 5(4): 303-7, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15507178